3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Drug News -

Pfizer sues P&G over mouthwash ads

Drug NewsMar 06, 06

Pfizer Inc. the maker of Listerine mouthwash on Friday sued Procter & Gamble Co. for falsely claiming in television ads that four out five dentists would recommend its rival brand Crest Pro-Health mouthwash.

“P&G’s false and misleading claims concerning Crest Pro-Health cause a substantial number of consumers to believe that this product is recommended by the vast majority of dentists—which is false—and that these dentists are recommending it for specific product-related reasons—which also is false,” the lawsuit filed in U.S. District Court in Manhattan, said.

A spokeswoman for P&G based said she had not seen the lawsuit and had no comment.

Pfizer said the commercials are intended to and do compare Crest Pro-Health with Listerine. Pfizer is seeking all of P&G’s profits made from the advertising claim.

P&G’s claim that four out of five dentists would recommend Crest Pro-Health is only backed up by a survey of 269 dentists who were paid $75 to participate, according to the lawsuit.

The Crest Pro-Health claims about dentists are made in three or more television commercials that have been airing since about December 2005, the lawsuit said.

Last month, P&G filed a lawsuit against Vi-Jon Industries, alleging that Vi-Jon’s mouthwash packaging and advertising claims infringe on its Crest Pro-Health mouthwash.



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  UGA ecologist finds another cause of antibiotic resistance
  New drug for neuroblastoma shows promise in phase I study
  Baclofen shows promise in patients with alcohol-induced liver disease
  Findings point to an ‘off switch’ for drug resistance in cancer
  Stopping statins may benefit terminally ill patients
  Cholesterol drug users may use pills as a license to overeat
  Pfizer lung cancer drug beats chemo for previously untreated patients
  Mass. General study identifies path to safer drugs for heart disease, cancer
  Gates Foundation awards Notre Dame $23 million for malaria, dengue studies
  Cancer drug protects against diabetes
  Malaria drug target raises hopes for new treatments

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site